Fu’s Subcutaneous Needling treatment for migraine without aura: a randomized controlled trial protocol
Abstract
Introduction Fu’s Subcutaneous Needling (FSN) is a novel acupuncture technique that has demonstrated significant efficacy in pain management. However, its effectiveness in treating migraine without aura (MWoA) has not been systematically validated. Therefore, this study aims to evaluate the analgesic efficacy of FSN and its impact on headache frequency and patients’ quality of life (QoL) in comparison with guideline-recommended pharmacotherapy (flunarizine hydrochloride). Additionally, this study will assess the influence of FSN on hemodynamic changes in the prefrontal cortex to further elucidate its underlying mechanisms. Methods This study is a randomized controlled clinical trial involving 44 participants, who are randomly allocated at a 1:1 ratio to either the FSN group or the medication group. Participants in the FSN group receive FSN treatment twice weekly for 4 weeks, while those in the medication group are administered 5 mg oral flunarizine hydrochloride capsules nightly for the same duration. Both groups are followed up for 3 months post-treatment. The primary outcome is the change in monthly migraine days (MMDs). From baseline after 4 weeks of treatment. Secondary outcome measures including the Migraine-Specific Quality of Life (MSQOL) score, headache diary records, Migraine Disability Assessment (MIDAS), Visual Analog Scale (VAS) scores and near-infrared spectroscopy (NIRS) are also used to validate clinical efficacy.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 44 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.